hotspot -WSS

hotspot

author：Wikipedia 2025-09-29 11:20:21 - browse：32874

Since the early days of the pandemic, long Covid has haunted us: Even a mild acute infection might leave you with life-altering consequences. And for many, that has, sadly, turned out to be the case. While research suggests long Covid rates are falling, it still affects millions. In June 2023, 6% of Americans reported experiencing long Covid.

But what if long Covid isn’t the right way to think about what they are going through?

On this episode of the First Opinion Podcast, I spoke with Steven Phillips and Michelle A. Williams, authors of a recent First Opinion essay titled, “Long Covid is a new name for an old syndrome.” Steven is a Global Virus Network board member and vice president for science and strategy at the COVID Collaborative; Michelle is the former dean and current Joan and Julius Jacobson professor of epidemiology and public health at the Harvard T.H. Chan School of Public Health.

“Michelle and I have come up with basically a new paradigm that says long Covid is really an old disease, and the more you do deep dives into the history of chronic fatigue syndrome and post-infectious fatigue syndromes, the more you realize that not only are there similarities, but the level of congruence between the two is strikingly high,” Steven said.

The purpose of this new paradigm is to “break the logjam” of the current long Covid discourse and “to try to provide a framework whereby people would think about long Covid in a different way in a way that would be more productive,” Michelle told me.

We discussed the history of post-infectious disease syndrome, what rethinking long Covid might mean for research, and the ways the health care system fails chronically ill patients.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Emergency workers more likely to restrain Black patients: study

WSS

Experts study whether long Covid risk adds up with each reinfection

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Lasker Awards 2023: Winners in biomedical research

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

FDA approves Moderna’s RSV vaccine, its second licensed product

Biotech stock slump in 2023: awaiting the turnaround

explore

hotspot

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA approves Moderna’s RSV vaccine, its second licensed product

Virginia high school admissions case could be legal follow

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Virginia high school admissions case could be legal follow

Eli Lilly’s Zepbound improved liver scarring in mid

The cancer drug shortage isn’t new — and neither are the solutions

Finland to offer bird flu vaccine to select groups of people, a possible global first

Medicare details structure of new drug price negotiation program

FDA panel to weigh approval of NurOwn, controversial ALS drug

knowledge

A new initiative will help leaders fight the next pandemic

Eli Lilly’s Zepbound improved liver scarring in mid

ASCO Daily Recap: CAR

Readout LOUD podcast: possible new ALS drug, artificial wombs

What Congress can do to address the rural doctor shortage

Intarcia’s device

hotspot

explore

hotspot

Wikipedia